FAQ

Quarterly and annual reports, as well as other regulatory filings, can be accessed on the Securities and Exchange Commision’s website: www.sec.gov.

Our fiscal year ends December 31.

We do not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations in our business.

Ernst & Young

Prior to October 23, 2023, RVL Pharmaceuticals plc’s transfer agent was Computershare. Computershare can be reached at:

Computer Share Investor Services
Computershare
P.O. Box 505000
Louisville, KY 40233-5000
1- 877-373-6374 (US, Canada, Puerto Rico)
1- 781-575-3100 (non-US)
www.computershare.com/investor

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

Email: web.queries@computershare.com

Shareholder Online Inquiries: https://www-us.computershare.com/investor/Contact

RVL Pharmaceuticals plc is represented by Ropes & Gray LLP and A&L Goodbody LLP.

RVL Pharmaceuticals plc began listing on the NASDAQ Global Market on October 18, 2018.

You can contact RVL Pharmaceuticals Investor Relations via email at: IR@RVLpharma.com.

RVL Pharmaceuticals plc is headquartered at 400 Crossing Boulevard, Bridgewater, NJ 08807 with an Ireland office at 3 Dublin Landings, North Wall Quay, Dublin 1, D01 C4E0, Ireland.